Please provide your email address to receive an email when new articles are posted on . Mycobacterial disease incidence was significantly higher among patients with vs. without allergic disease.

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027Data from the ongoing parallel BROADEN2 Phase 2b atopic ...

Kymera Therapeutics started dosing patients in its BREADTH Phase 2b trial of KT-621, an oral STAT6 degrader, in moderate to severe eosinophilic asthma. KT-621 is also being evaluated in parallel for ...

Rapt Therapeutics aim to bring patients oral alternatives to injectable or infused immunology medications has hit a setback. A Rapt drug candidate in mid-stage clinical development in atopic ...

A new study published in the Journal of the American Medical Association showed that asthma, allergic rhinitis, and atopic dermatitis are somewhat more common in children conceived with ...

"With regard to the prevalence of comorbidities, the burden associated with severe [non-eosinophilic] asthma was heavy due to more comorbidities. Allergic asthma is as frequent in [eosinophilic] as in ...

Living with allergic asthma means managing a variety of potential triggers, some of which might surprise you. Though most people are familiar with the common allergic asthma triggers—like pollen, dust ...

Asthma is a chronic respiratory illness that can get triggered by dust, pollens and other allergens. Allergic asthma is the condition in which asthma attacks specifically get precipitated by allergen ...